Urosodeoxycholic acid
Oral suspension
indicated in the treatment of primary biliary cholangitis (PBC) and for the dissolution of radiolucent gallstones in patients with a functioning gall bladder
Paediatric population
Hepatobiliary disorders associated with cystic fibrosis in children aged 1 month to 18 years.
The daily dose depends on body weight, and is approximately 14 ± 2 mg UDCA per kg of body weight.